Arteriosclerosis and Thrombosis, Vol 14, 381-385, Copyright © 1994 by American Heart Association

ARTICLES

Molecular characterization of human hepatic lipase deficiency. In vitro expression of two naturally occurring mutations

A Durstenfeld, O Ben-Zeev, K Reue, G Stahnke and MH Doolittle
Lipid Research, Veterans Administration Wadsworth Medical Center, Los Angeles, CA 90073.

Individuals with hepatic lipase (HL) deficiency are often characterized by elevated levels of triglycerides and cholesterol and may be subject to premature atherosclerosis. Missense mutations in the HL gene have been identified in two affected families: substitutions of serine for phenylalanine at amino acid 267 and threonine for methionine at amino acid 383 (S267F and T383M, respectively). To confirm the role of S267F and T383M, respectively). To confirm the role of mutations separately into human HL cDNA by site-directed mutagenesis, and the resulting constructs were independently expressed in COS cells. HL activity and mass were measured and compared with wild-type HL transfectants to determine the effect of these mutations on lipase activity and secretion. Although similar amounts of HL protein were detected intracellularly after transfection with the wild-type and mutant constructs, S267F and T383M HL activity levels were markedly decreased: in S267F, no HL activity was detected, and activity levels in T383M were 38% of wild-type HL. Heparin-induced secretion of the two HL mutants was also severely affected: no detectable activity could be measured in the media of S267F, although some inactive mass (12% of wild-type HL) was secreted; mutant T383M secreted 4% and 20% of wild- type activity and mass, respectively. These results indicate that the single amino acid substitution present in HL S267F is sufficient to render the enzyme completely nonfunctional; in contrast, the T383M mutant retains partial activity but is poorly secreted. Thus, these defects appear capable of accounting for the HL-deficient phenotypes exhibited by individuals carrying the T383M and S267F mutations.

This article has been cited by other articles:

				R. J. Brown, A. C. Edmondson, N. Griffon, T. B. Hill, I. V. Fuki, K. O. Badellino, M. Li, M. L. Wolfe, M. P. Reilly, and D. J. Rader A naturally occurring variant of endothelial lipase associated with elevated HDL exhibits impaired synthesis J. Lipid Res., September 1, 2009; 50(9): 1910 - 1916. [Abstract] [Full Text] [PDF]

				S. Fazio and M. F. Linton Elevated High-Density Lipoprotein (HDL) Levels due to Hepatic Lipase Mutations Do Not Reduce Cardiovascular Disease Risk: Another Strike against the HDL Dogma J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1081 - 1083. [Full Text] [PDF]

				T. H. Johannsen, P. R. Kamstrup, R. V. Andersen, G. B. Jensen, H. Sillesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard Hepatic Lipase, Genetically Elevated High-Density Lipoprotein, and Risk of Ischemic Cardiovascular Disease J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1264 - 1273. [Abstract] [Full Text] [PDF]

				I. L. Ruel, P. Couture, J. S. Cohn, A. Bensadoun, M. Marcil, and B. Lamarche Evidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolism J. Lipid Res., August 1, 2004; 45(8): 1528 - 1537. [Abstract] [Full Text] [PDF]

				I. L. Ruel, P. Couture, C. Gagne, Y. Deshaies, J. Simard, R. A. Hegele, and B. Lamarche Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians J. Lipid Res., August 1, 2003; 44(8): 1508 - 1514. [Abstract] [Full Text] [PDF]

				V. Briquet-Laugier, O. Ben-Zeev, A. White, and M. H. Doolittle cld and lec23 are disparate mutations that affect maturation of lipoprotein lipase in the endoplasmic reticulum J. Lipid Res., November 1, 1999; 40(11): 2044 - 2058. [Abstract] [Full Text]

				R. A. Hegele, W. C. Breckenridge, D. W. Cox, G. F. Maguire, J. A. Little, and P. W. Connelly Elevated LDL Triglyceride Concentrations in Subjects Heterozygous for the Hepatic Lipase S267F Variant Arterioscler Thromb Vasc Biol, August 1, 1998; 18(8): 1212 - 1216. [Abstract] [Full Text] [PDF]

				H. Jansen, A. J. M. Verhoeven, L. Weeks, J. J. P. Kastelein, D. J. J. Halley, A. van den Ouweland, J. W. Jukema, J. C. Seidell, and J. C. Birkenhager Common C-to-T Substitution at Position -480 of the Hepatic Lipase Promoter Associated With a Lowered Lipase Activity in Coronary Artery Disease Patients Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2837 - 2842. [Abstract] [Full Text]

				R. A. Wetsel, J. Kulics, M.-L. Lokki, P. Kiepiela, H. Akama, C. A. C. Johnson, P. Densen, and H. R. Colten Type II Human Complement C2 Deficiency J. Biol. Chem., March 8, 1996; 271(10): 5824 - 5831. [Abstract] [Full Text] [PDF]

				G. E. Homanics, H. V. de Silva, J.ús Osada, S. H. Zhang, H. Wong, J. Borensztajn, and N. Maeda Mild Dyslipidemia in Mice following Targeted Inactivation of the Hepatic Lipase Gene J. Biol. Chem., February 17, 1995; 270(7): 2974 - 2980. [Abstract] [Full Text] [PDF]